Sotatercept Evidence Report Calculates Price Benchmark as It Awaits Review for Treatment of PAH

A Biologics License Application has been submitted to the FDA review for sotatercept in the treatment of pulmonary arterial hypertension.

Related Keywords

,Institute For Clinical ,World Health Organization ,Economic Review ,Hypertension Concept ,Vector Market ,Biologics License Application ,Pulmonary Arterial Hypertension ,Pah ,Sotatercept ,Fda Approval ,Fda ,